BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Buonaguro L, Mauriello A, Cavalluzzo B, Petrizzo A, Tagliamonte M. Immunotherapy in hepatocellular carcinoma. Ann Hepatol. 2019;18:291-297. [PMID: 31047849 DOI: 10.1016/j.aohep.2019.04.003] [Cited by in Crossref: 24] [Cited by in F6Publishing: 33] [Article Influence: 8.0] [Reference Citation Analysis]
Number Citing Articles
1 Yu Z, Guo J, Liu Y, Wang M, Liu Z, Gao Y, Huang L. Nano delivery of simvastatin targets liver sinusoidal endothelial cells to remodel tumor microenvironment for hepatocellular carcinoma. J Nanobiotechnology 2022;20:9. [PMID: 34983554 DOI: 10.1186/s12951-021-01205-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
2 Liu N, Chang CW, Steer CJ, Wang XW, Song G. MicroRNA-15a/16-1 Prevents Hepatocellular Carcinoma by Disrupting the Communication Between Kupffer Cells and Regulatory T Cells. Gastroenterology 2021:S0016-5085(21)03652-0. [PMID: 34678217 DOI: 10.1053/j.gastro.2021.10.015] [Cited by in Crossref: 10] [Cited by in F6Publishing: 9] [Article Influence: 10.0] [Reference Citation Analysis]
3 Liang Y, Chen X, Tao Z, Ma M, Adah D, Li X, Dai L, Ding W, Fanuel S, Zhao S, Qin L, Chen X, Zhang X. Plasmodium infection prevents recurrence and metastasis of hepatocellular carcinoma possibly via inhibition of the epithelial‑mesenchymal transition. Mol Med Rep 2021;23:418. [PMID: 33846776 DOI: 10.3892/mmr.2021.12057] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
4 Martín-Sierra C, Martins R, Coucelo M, Abrantes AM, Oliveira RC, Tralhão JG, Botelho MF, Furtado E, Domingues MR, Paiva A, Laranjeira P. Elevated soluble TNFα levels and upregulated TNFα mRNA expression in purified peripheral blood monocyte subsets associated with high-grade hepatocellular carcinoma. J Inflamm (Lond) 2020;17:14. [PMID: 32256215 DOI: 10.1186/s12950-020-00243-7] [Reference Citation Analysis]
5 Lu L, Jiang J, Zhan M, Zhang H, Wang QT, Sun SN, Guo XK, Yin H, Wei Y, Li SY, Liu JO, Li Y, He YW. Targeting Tumor-Associated Antigens in Hepatocellular Carcinoma for Immunotherapy: Past Pitfalls and Future Strategies. Hepatology 2021;73:821-32. [PMID: 32767586 DOI: 10.1002/hep.31502] [Cited by in Crossref: 17] [Cited by in F6Publishing: 11] [Article Influence: 17.0] [Reference Citation Analysis]
6 Polidoro MA, Mikulak J, Cazzetta V, Lleo A, Mavilio D, Torzilli G, Donadon M. Tumor microenvironment in primary liver tumors: A challenging role of natural killer cells. World J Gastroenterol 2020; 26(33): 4900-4918 [PMID: 32952338 DOI: 10.3748/wjg.v26.i33.4900] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 8] [Article Influence: 4.5] [Reference Citation Analysis]
7 Zhong C, Li Y, Yang J, Jin S, Chen G, Li D, Fan X, Lin H. Immunotherapy for Hepatocellular Carcinoma: Current Limits and Prospects. Front Oncol 2021;11:589680. [PMID: 33854960 DOI: 10.3389/fonc.2021.589680] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
8 Li Y, Zhang R, Xu Z, Wang Z. Advances in Nanoliposomes for the Diagnosis and Treatment of Liver Cancer. IJN 2022;Volume 17:909-25. [DOI: 10.2147/ijn.s349426] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Fu H, Liu X, Jin L, Lang J, Hu Z, Mao W, Cheng C, Shou Q. Safflower yellow reduces DEN-induced hepatocellular carcinoma by enhancing liver immune infiltration through promotion of collagen degradation and modulation of gut microbiota. Food Funct 2021;12:10632-43. [PMID: 34585698 DOI: 10.1039/d1fo01321a] [Reference Citation Analysis]
10 Wong CN, Fessas P, Dominy K, Mauri FA, Kaneko T, Parcq PD, Khorashad J, Toniutto P, Goldin RD, Avellini C, Pinato DJ. Qualification of tumour mutational burden by targeted next-generation sequencing as a biomarker in hepatocellular carcinoma. Liver Int. 2021;41:192-203. [PMID: 33098208 DOI: 10.1111/liv.14706] [Cited by in Crossref: 4] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
11 Montella L, Sarno F, Ambrosino A, Facchini S, D'Antò M, Laterza MM, Fasano M, Quarata E, Ranucci RAN, Altucci L, Berretta M, Facchini G. The Role of Immunotherapy in a Tolerogenic Environment: Current and Future Perspectives for Hepatocellular Carcinoma. Cells 2021;10:1909. [PMID: 34440678 DOI: 10.3390/cells10081909] [Reference Citation Analysis]
12 Liao J, Zeng D, Li J, Hua Q, Xiao Z, He C, Mao K, Zhu L, Chu Y, Wen W, Zheng L, Wu Y. Targeting adenosinergic pathway enhances the anti-tumor efficacy of sorafenib in hepatocellular carcinoma. Hepatol Int 2020;14:80-95. [DOI: 10.1007/s12072-019-10003-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
13 Liu BQ, Bao ZY, Zhu JY, Liu H. Fibrinogen-like protein 2 promotes the accumulation of myeloid-derived suppressor cells in the hepatocellular carcinoma tumor microenvironment. Oncol Lett 2021;21:47. [PMID: 33281958 DOI: 10.3892/ol.2020.12308] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
14 Murali M, Kumar AR, Nair B, Pavithran K, Devan AR, Pradeep GK, Nath LR. Antibody-drug conjugate as targeted therapeutics against hepatocellular carcinoma: preclinical studies and clinical relevance. Clin Transl Oncol 2021. [PMID: 34595736 DOI: 10.1007/s12094-021-02707-5] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
15 Hochnadel I, Hoenicke L, Petriv N, Neubert L, Reinhard E, Hirsch T, Alfonso JCL, Suo H, Longerich T, Geffers R, Lichtinghagen R, Guzmán CA, Wedemeyer H, Lenzen H, Manns MP, Bruder D, Yevsa T. Safety and efficacy of prophylactic and therapeutic vaccine based on live-attenuated Listeria monocytogenes in hepatobiliary cancers. Oncogene 2022. [PMID: 35173308 DOI: 10.1038/s41388-022-02222-z] [Reference Citation Analysis]
16 Rai V, Mukherjee S. Targets of immunotherapy for hepatocellular carcinoma: An update. World J Hepatol 2022; 14(1): 140-157 [DOI: 10.4254/wjh.v14.i1.140] [Reference Citation Analysis]
17 Zeng C, Zhang L, Luo C, Yang C, Huang X, Fan L, Li J, Chen F, Luo Z. A stratification model of hepatocellular carcinoma based on expression profiles of cells in the tumor microenvironment. BMC Cancer 2022;22. [DOI: 10.1186/s12885-022-09647-5] [Reference Citation Analysis]
18 Moeckli B, Ivanics T, Claasen M, Toso C, Sapisochin G. Recent developments and ongoing trials in transplant oncology. Liver Int 2020;40:2326-44. [PMID: 33021344 DOI: 10.1111/liv.14621] [Reference Citation Analysis]
19 Rizzo A, Ricci AD, Gadaleta-Caldarola G, Brandi G. First-line immune checkpoint inhibitor-based combinations in unresectable hepatocellular carcinoma: current management and future challenges. Expert Rev Gastroenterol Hepatol 2021;15:1245-51. [PMID: 34431725 DOI: 10.1080/17474124.2021.1973431] [Reference Citation Analysis]
20 Charalampakis N, Papageorgiou G, Tsakatikas S, Fioretzaki R, Kole C, Kykalos S, Tolia M, Schizas D. Immunotherapy for cholangiocarcinoma: a 2021 update. Immunotherapy 2021;13:1113-34. [PMID: 34190581 DOI: 10.2217/imt-2021-0126] [Reference Citation Analysis]
21 Wang L, Yang Z, Cao Y. Regulatory T cell and activated natural killer cell infiltration in hepatocellular carcinoma: immune cell profiling using the CIBERSORT. Ann Transl Med 2020;8:1483. [PMID: 33313228 DOI: 10.21037/atm-20-5830] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 3.5] [Reference Citation Analysis]
22 Zhou ZF, Peng F, Li JY, Ye YB. Intratumoral IL-12 Gene Therapy Inhibits Tumor Growth In A HCC-Hu-PBL-NOD/SCID Murine Model. Onco Targets Ther 2019;12:7773-84. [PMID: 31571927 DOI: 10.2147/OTT.S222097] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
23 Melillo G, Chand V, Yovine A, Gupta A, Massacesi C. Curative-Intent Treatment with Durvalumab in Early-Stage Cancers. Adv Ther 2021;38:2759-78. [PMID: 33881745 DOI: 10.1007/s12325-021-01675-0] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
24 Wang H, Lu Z, Zhao X. Tumorigenesis, diagnosis, and therapeutic potential of exosomes in liver cancer. J Hematol Oncol. 2019;12:133. [PMID: 31815633 DOI: 10.1186/s13045-019-0806-6] [Cited by in Crossref: 33] [Cited by in F6Publishing: 44] [Article Influence: 11.0] [Reference Citation Analysis]
25 Yuan L, Bing Z, Han J, An X, Liu X, Li R, Wang C, Sun X, Yang L, Yang K. Study on the anti-tumor mechanism related to immune microenvironment of Bombyx Batryticatus on viral and non-viral infections of hepatocellular carcinoma. Biomed Pharmacother 2020;124:109838. [PMID: 31981943 DOI: 10.1016/j.biopha.2020.109838] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
26 Li Z, Gong H, Liu Q, Wu W, Cheng J, Mei Y, Chen Y, Zheng H, Yu X, Zhong S, Li Y. Identification of an HLA-A*24:02-restricted α-fetoprotein signal peptide-derived antigen and its specific T-cell receptor for T-cell immunotherapy. Immunology 2020;159:384-92. [PMID: 31849039 DOI: 10.1111/imm.13168] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
27 Yan H, Chen Y, Wang K, Yu L, Huang X, Li Q, Xie Y, Lin J, He Y, Yi X, Wang Y, Chen L, Ding Y, Li Y. Identification of immune landscape signatures associated with clinical and prognostic features of hepatocellular carcinoma. Aging (Albany NY) 2020;12:19641-59. [PMID: 33049716 DOI: 10.18632/aging.103977] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
28 Akkın S, Varan G, Bilensoy E. A Review on Cancer Immunotherapy and Applications of Nanotechnology to Chemoimmunotherapy of Different Cancers. Molecules 2021;26:3382. [PMID: 34205019 DOI: 10.3390/molecules26113382] [Reference Citation Analysis]
29 Tang X, Shu Z, Zhang W, Cheng L, Yu J, Zhang M, Zheng S. Clinical significance of the immune cell landscape in hepatocellular carcinoma patients with different degrees of fibrosis. Ann Transl Med 2019;7:528. [PMID: 31807510 DOI: 10.21037/atm.2019.09.122] [Cited by in Crossref: 7] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
30 Shrestha R, Prithviraj P, Bridle KR, Crawford DHG, Jayachandran A. Combined Inhibition of TGF-β1-Induced EMT and PD-L1 Silencing Re-Sensitizes Hepatocellular Carcinoma to Sorafenib Treatment. J Clin Med 2021;10:1889. [PMID: 33925488 DOI: 10.3390/jcm10091889] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
31 Liu HT, Jiang MJ, Deng ZJ, Li L, Huang JL, Liu ZX, Li LQ, Zhong JH. Immune Checkpoint Inhibitors in Hepatocellular Carcinoma: Current Progresses and Challenges. Front Oncol 2021;11:737497. [PMID: 34745958 DOI: 10.3389/fonc.2021.737497] [Reference Citation Analysis]
32 Kole C, Charalampakis N, Tsakatikas S, Vailas M, Moris D, Gkotsis E, Kykalos S, Karamouzis MV, Schizas D. Immunotherapy for Hepatocellular Carcinoma: A 2021 Update. Cancers (Basel) 2020;12:E2859. [PMID: 33020428 DOI: 10.3390/cancers12102859] [Cited by in Crossref: 14] [Cited by in F6Publishing: 18] [Article Influence: 7.0] [Reference Citation Analysis]
33 Caraballo Galva LD, Cai L, Shao Y, He Y. Engineering T cells for immunotherapy of primary human hepatocellular carcinoma. J Genet Genomics. 2020;47:1-15. [PMID: 32089500 DOI: 10.1016/j.jgg.2020.01.002] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
34 Fasano R, Shadbad MA, Brunetti O, Argentiero A, Calabrese A, Nardulli P, Calbi R, Baradaran B, Silvestris N. Immunotherapy for Hepatocellular Carcinoma: New Prospects for the Cancer Therapy. Life (Basel) 2021;11:1355. [PMID: 34947886 DOI: 10.3390/life11121355] [Reference Citation Analysis]
35 Zhou Z, Lin L, An Y, Zhan M, Chen Y, Cai M, Zhu X, Lu L, Zhu K. The Combination Immunotherapy of TLR9 Agonist and OX40 Agonist via Intratumoural Injection for Hepatocellular Carcinoma. J Hepatocell Carcinoma 2021;8:529-43. [PMID: 34136421 DOI: 10.2147/JHC.S301375] [Reference Citation Analysis]
36 Buonaguro L. Human Hepatocellular Carcinoma (HCC). Cancers (Basel) 2020;12:E3739. [PMID: 33322652 DOI: 10.3390/cancers12123739] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
37 Gao Y, Lyu L, Feng Y, Li F, Hu Y. A review of cutting-edge therapies for hepatocellular carcinoma (HCC): Perspectives from patents. Int J Med Sci 2021;18:3066-81. [PMID: 34400877 DOI: 10.7150/ijms.59930] [Reference Citation Analysis]
38 Beshnova D, Ye J, Onabolu O, Moon B, Zheng W, Fu YX, Brugarolas J, Lea J, Li B. De novo prediction of cancer-associated T cell receptors for noninvasive cancer detection. Sci Transl Med 2020;12:eaaz3738. [PMID: 32817363 DOI: 10.1126/scitranslmed.aaz3738] [Cited by in Crossref: 9] [Cited by in F6Publishing: 5] [Article Influence: 9.0] [Reference Citation Analysis]
39 Roudi R, D'Angelo A, Sirico M, Sobhani N. Immunotherapeutic treatments in hepatocellular carcinoma; achievements, challenges and future prospects. Int Immunopharmacol 2021;101:108322. [PMID: 34735916 DOI: 10.1016/j.intimp.2021.108322] [Reference Citation Analysis]
40 Huang X, Yang C, Wang J, Sun T, Xiong H. Integrative analysis of DNA methylation and gene expression reveals distinct hepatocellular carcinoma subtypes with therapeutic implications. Aging (Albany NY) 2020;12:4970-95. [PMID: 32201399 DOI: 10.18632/aging.102923] [Cited by in Crossref: 2] [Cited by in F6Publishing: 5] [Article Influence: 1.0] [Reference Citation Analysis]
41 Jayant K, Habib N, Huang KW, Podda M, Warwick J, Arasaradnam R. Immunological Basis of Genesis of Hepatocellular Carcinoma: Unique Challenges and Potential Opportunities through Immunomodulation. Vaccines (Basel) 2020;8:E247. [PMID: 32456200 DOI: 10.3390/vaccines8020247] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 2.5] [Reference Citation Analysis]
42 Jayant K, Habib N, Huang KW, Warwick J, Arasaradnam R. Recent Advances: The Imbalance of Immune Cells and Cytokines in the Pathogenesis of Hepatocellular Carcinoma. Diagnostics (Basel). 2020;10. [PMID: 32466214 DOI: 10.3390/diagnostics10050338] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
43 Lin Z, Xie YZ, Zhao MC, Hou PP, Tang J, Chen GL. Xanthine dehydrogenase as a prognostic biomarker related to tumor immunology in hepatocellular carcinoma. Cancer Cell Int 2021;21:475. [PMID: 34496841 DOI: 10.1186/s12935-021-02173-7] [Reference Citation Analysis]